These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 23498828)

  • 1. Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
    Zhao XY; Rakhda MI; Wang TI; Jia JD
    Transplant Proc; 2013 Mar; 45(2):824-7. PubMed ID: 23498828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
    Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
    Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2233-6. PubMed ID: 21839242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.
    Donato MF; Fabrizi F; Fogazzi GB; Cresseri D; Passerini P; Martin P; Messa P
    Int J Artif Organs; 2013 Jan; 36(1):63-8. PubMed ID: 23280083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
    Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin.
    Götz G; Schön MR; Haefker A; Neuhaus R; Berg T; Hopf U; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):2104-6. PubMed ID: 9723407
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
    Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
    Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation in a patient with hepatitis B, C and D coinfection associated with hepatocellular carcinoma: a management strategy for a rare condition. Case report.
    Dantas LC; Genzini T; Miranda MP; Santos RG; Siqueira NG; Weirich J; Lobato CM
    Sao Paulo Med J; 2015; 133(6):525-30. PubMed ID: 26176835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case.
    Takeishi K; Shirabe K; Toshima T; Ikegami T; Morita K; Fukuhara T; Motomura T; Mano Y; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
    Surg Today; 2011 Jul; 41(7):1016-9. PubMed ID: 21748625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis.
    Mederacke I; Witte T; Wedemeyer H; Meyer-Olson D
    Ann Rheum Dis; 2011 Jul; 70(7):1343-4. PubMed ID: 21131645
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
    Hamzaoui L; El Bouchtili S; Siai K; Mahmoudi M; Azzouz MM
    Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):e16-20. PubMed ID: 22959099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
    Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
    Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of recurrent hepatitis C virus after liver transplantation.
    Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
    World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
    Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
    O'Leary JG; McKenna GJ; Klintmalm GB; Davis GL
    Liver Transpl; 2013 Apr; 19(4):463-5. PubMed ID: 23408534
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.